{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:55:19Z","timestamp":1791395719554,"version":"4.3.3"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.mam.2026.101476","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T04:33:57Z","timestamp":1776573237000},"page":"101476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets"],"prefix":"10.1016","volume":"109","author":[{"given":"Divya","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila A.","family":"Seyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"den Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick A.","family":"Kuburich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Schupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Safran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5918-4276","authenticated-orcid":false,"given":"Sendurai A.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"28","key":"10.1016\/j.mam.2026.101476_bib1","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302485120","article-title":"Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors","volume":"120","author":"Akkapeddi","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.gassur.2024.01.007","article-title":"Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma","volume":"28","author":"Akumuo","year":"2024","journal-title":"J. Gastrointest. Surg."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.mam.2026.101476_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12885-016-2048-0","article-title":"RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes","volume":"16","author":"Amato","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12029-015-9734-z","article-title":"A meta-analysis of randomized clinical trials of chemoradiation therapy in locally advanced pancreatic cancer","volume":"46","author":"Ambe","year":"2015","journal-title":"J. Gastrointest. Cancer"},{"issue":"23","key":"10.1016\/j.mam.2026.101476_bib6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000477562","article-title":"Clinical benefit from trametinib in a patient with appendiceal adenocarcinoma with a GNAS R201H mutation","volume":"10","author":"Ang","year":"2017","journal-title":"Case Rep. Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib8","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","article-title":"ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications","volume":"18","author":"Armstrong","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.mpa.0000226883.55828.e9","article-title":"Ethanol and the tobacco-specific carcinogen, NNK, contribute to signaling in immortalized human pancreatic duct epithelial cells","volume":"33","author":"Askari","year":"2006","journal-title":"Pancreas"},{"issue":"7592","key":"10.1016\/j.mam.2026.101476_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s12885-024-12463-8","article-title":"Early detection of pancreatic cancer by liquid biopsy \"PANLIPSY\": a french nation-wide study project","volume":"24","author":"Bardol","year":"2024","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis","volume":"3","author":"Barriga","year":"2022","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","article-title":"Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy","volume":"4","author":"Barthel","year":"2023","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/00000658-200212000-00005","article-title":"CDKN2A germline mutations in familial pancreatic cancer","volume":"236","author":"Bartsch","year":"2002","journal-title":"Ann. Surg."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/MPA.0000000000001383","article-title":"Cigarette smoking and mortality in patients with pancreatic cancer: a systematic review and meta-analysis","volume":"48","author":"Ben","year":"2019","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-023-02879-8","article-title":"ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells","volume":"43","author":"Bergonzini","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s42003-024-06087-8","article-title":"Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-siglec interactions","volume":"7","author":"Boelaars","year":"2024","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/occmed\/kqad050","article-title":"Duration-response association between occupational exposure and pancreatic cancer risk: meta-analysis","volume":"73","author":"Boonhat","year":"2023","journal-title":"Occup. Med. (Lond.)"},{"issue":"18","key":"10.1016\/j.mam.2026.101476_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150453","article-title":"SWI\/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer","volume":"6","author":"Botta","year":"2021","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib20","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mam.2026.101476_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-230X-9-93","article-title":"A proposal for a new clinical classification of chronic pancreatitis","volume":"9","author":"Buchler","year":"2009","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib22","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/s41467-024-46811-w","article-title":"Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer","volume":"15","author":"Bulle","year":"2024","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.mam.2026.101476_bib23","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3748\/wjg.v29.i18.2864","article-title":"Endoscopic ultrasound-guided fine-needle aspiration pancreatic adenocarcinoma samples yield adequate DNA for next-generation sequencing: a cohort analysis","volume":"29","author":"Bunduc","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib24","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mam.2026.101476_bib25","article-title":"Combined PI3K and MAPK inhibition synergizes to suppress PDAC","author":"Bye","year":"2023","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semcancer.2003.09.015","article-title":"Oncogenic ras and its role in tumor cell invasion and metastasis","volume":"14","author":"Campbell","year":"2004","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","year":"2017","journal-title":"Cancer Cell"},{"issue":"7781","key":"10.1016\/j.mam.2026.101476_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib29","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1038\/s41591-023-02640-w","article-title":"Large-scale pancreatic cancer detection via non-contrast CT and deep learning","volume":"29","author":"Cao","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbrc.2009.03.068","article-title":"Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic kras","volume":"382","author":"Carriere","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0020-1383(88)90174-X","article-title":"The treatment of femoral shortening after intramedullary nailing","volume":"19","author":"Chadwick","year":"1988","journal-title":"Injury"},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004485","article-title":"Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer","volume":"10","author":"Chakrabarti","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/01635581.2012.725502","article-title":"Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area","volume":"65","author":"Chan","year":"2013","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.mam.2026.101476_bib34","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1008585","article-title":"Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer","volume":"16","author":"Chen","year":"2026","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103647","article-title":"4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone provokes progression from chronic pancreatitis to pancreatic intraepithelial neoplasia","volume":"25","author":"Chen","year":"2022","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12957-019-1732-3","article-title":"Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data","volume":"17","author":"Chikhladze","year":"2019","journal-title":"World J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.cell.2020.03.062","article-title":"Endocrine-Exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma","volume":"181","author":"Chung","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.soc.2005.05.006","article-title":"Pancreaticoduodenectomy (Whipple operation)","volume":"14","author":"Clancy","year":"2005","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.mam.2026.101476_bib44","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.mam.2026.101476_bib45","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7793","key":"10.1016\/j.mam.2026.101476_bib46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.mam.2026.101476_bib47","article-title":"Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: Mayo Clinic experience","volume":"7","author":"Coston","year":"2023","journal-title":"JCO Precis. Oncol."},{"issue":"21","key":"10.1016\/j.mam.2026.101476_bib48","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.cell.2022.09.019","article-title":"State-selective modulation of heterotrimeric Galphas signaling with macrocyclic peptides","volume":"185","author":"Dai","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib49","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","article-title":"Oncogenic KRAS-Driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment","volume":"10","author":"Dey","year":"2020","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib51","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.mam.2026.101476_bib54","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","article-title":"Combination of the MTA-Cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors is an effective treatment strategy for MTAP-Deleted KRAS-Mutant pancreatic cancer","volume":"85","author":"Drizyte-Miller","year":"2025","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.mam.2026.101476_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191939","article-title":"KRAS: the Achilles' heel of pancreas cancer biology","volume":"135","author":"Drizyte-Miller","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mam.2026.101476_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116685","article-title":"Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy","volume":"232","author":"Escalera-Anzola","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2026.101476_bib57","first-page":"419","article-title":"Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy","volume":"3","author":"Faller","year":"2009","journal-title":"Biologics"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/gutjnl-2016-312580","article-title":"Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study","volume":"67","author":"Fan","year":"2018","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/gutjnl-2011-300784","article-title":"Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer","volume":"61","author":"Farrell","year":"2012","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.mam.2026.101476_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003109","article-title":"Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei","volume":"9","author":"Flatmark","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6356","key":"10.1016\/j.mam.2026.101476_bib61","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12937-021-00723-3","article-title":"Dietary intake of fatty acids and risk of pancreatic cancer: Golestan cohort study","volume":"20","author":"Ghamarzad Shishavan","year":"2021","journal-title":"Nutr. J."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082331","article-title":"Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells","volume":"12","author":"Gnanasekaran","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-Mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","article-title":"Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer","volume":"70","author":"Gout","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib66","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","article-title":"Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer","volume":"70","author":"Gout","year":"2021","journal-title":"Gut"},{"issue":"2\u20133","key":"10.1016\/j.mam.2026.101476_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000085269","article-title":"Increased central memory T cells in patients with chronic pancreatitis","volume":"5","author":"Grundsten","year":"2005","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.6004\/jnccn.2020.7641","article-title":"Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature","volume":"19","author":"Gupta","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides Insight toward therapeutic susceptibility of KRAS-Mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides Insight toward therapeutic susceptibility of KRAS-Mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11040653","article-title":"The prognostic impact of HER2 genetic and protein expression in pancreatic Carcinoma-HER2 protein and gene in pancreatic cancer","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib73","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib74","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","article-title":"The pancreatic cancer genome revisited","volume":"18","author":"Hayashi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib75","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.18632\/oncotarget.2972","article-title":"Molecular landscape of pancreatic cancer: implications for current clinical trials","volume":"6","author":"Heestand","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.mam.2026.101476_bib76","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/0008-5472.CAN-13-2923","article-title":"CDK4\/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers","volume":"74","author":"Heilmann","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(23)00451-X","article-title":"The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned","volume":"9","author":"Henault","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib79","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41568-022-00530-w","article-title":"Epithelial and stromal co-evolution and complicity in pancreatic cancer","volume":"23","author":"Hingorani","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib83","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"Halo 202: randomized phase II Study of PEGPH20 plus Nab-Paclitaxel\/Gemcitabine versus Nab-Paclitaxel\/Gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.mam.2026.101476_bib84","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1158\/0008-5472.CAN-20-0414","article-title":"MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer","volume":"81","author":"Hu","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib86","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.cgh.2019.11.043","article-title":"New-Onset diabetes, longitudinal trends in metabolic markers, and risk of pancreatic cancer in a heterogeneous population","volume":"18","author":"Huang","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib87","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ccell.2021.06.017","article-title":"Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity","volume":"39","author":"Hutton","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib88","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","article-title":"Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment","volume":"54","author":"Hwang","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mam.2026.101476_bib89","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.csbj.2022.08.064","article-title":"Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma","volume":"20","author":"Hyun","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib90","article-title":"A blood-based metabolomic signature predictive of risk for pancreatic cancer","volume":"4","author":"Irajizad","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib91","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41467-021-21736-w","article-title":"KRAS drives immune evasion in a genetic model of pancreatic cancer","volume":"12","author":"Ischenko","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13061078","article-title":"Next-Generation sequencing analysis of pancreatic cancer using residual liquid cytology specimens from Endoscopic ultrasound-guided fine-needle biopsy: a prospective comparative Study with tissue specimens","volume":"13","author":"Iwaya","year":"2023","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with Gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.mam.2026.101476_bib94","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3389\/fonc.2020.01220","article-title":"Circulating Tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer","volume":"10","author":"Jiang","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib95","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-023-02790-x","article-title":"Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mnfr.201000420","article-title":"Dietary factors and pancreatic cancer: the role of food bioactive compounds","volume":"55","author":"Johnson","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib97","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1158\/0008-5472.CAN-25-0018","article-title":"Mutant and wild-type RAS crosstalk and stoichiometric deficiencies are determinants of sensitivity to targeted therapies in KRASG12R pancreatic ductal adenocarcinoma","volume":"86","author":"Kamgar","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2026.101476_bib98","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijsu.2018.01.041","article-title":"The outcomes and complications of pancreaticoduodenectomy (whipple procedure): cross sectional study","volume":"52","author":"Karim","year":"2018","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib99","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MPA.0000000000001762","article-title":"Artificial intelligence and early detection of pancreatic cancer: 2020 summative review","volume":"50","author":"Kenner","year":"2021","journal-title":"Pancreas"},{"issue":"34","key":"10.1016\/j.mam.2026.101476_bib101","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III Study of active maintenance olaparib versus placebo for germline BRCA-Mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib103","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jamcollsurg.2009.12.033","article-title":"A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate?","volume":"210","author":"Kooby","year":"2010","journal-title":"J. Am. Coll. Surg."},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2188\/jea.JE20160193","article-title":"Body-Mass Index and pancreatic cancer incidence: a pooled analysis of nine population-based cohort studies with more than 340,000 Japanese subjects","volume":"28","author":"Koyanagi","year":"2018","journal-title":"J. Epidemiol."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105881","article-title":"ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance","volume":"26","author":"Kuo","year":"2023","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib107","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib108","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/bjc.2011.585","article-title":"Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies","volume":"106","author":"Larsson","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib109","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOG.0b013e328349e2f8","article-title":"Genetics of pancreatitis","volume":"27","author":"LaRusch","year":"2011","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030761","article-title":"Pancreatic cancer in chronic pancreatitis: pathogenesis and diagnostic approach","volume":"15","author":"Le Cosquer","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib111","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mc.20771","article-title":"Diabetes and pancreatic cancer","volume":"51","author":"Li","year":"2012","journal-title":"Mol. Carcinog."},{"issue":"24","key":"10.1016\/j.mam.2026.101476_bib112","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1001\/jama.2009.886","article-title":"Body mass index and risk, age of onset, and survival in patients with pancreatic cancer","volume":"301","author":"Li","year":"2009","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mam.2026.101476_bib113","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41419-024-07138-y","article-title":"cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA\/PPA2c\/mTORC1 axis","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.mam.2026.101476_bib114","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib115","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S2589-7500(20)30078-9","article-title":"Deep learning to distinguish pancreatic cancer tissue from non-cancerous pancreatic tissue: a retrospective study with cross-racial external validation","volume":"2","author":"Liu","year":"2020","journal-title":"Lancet Digit. Health"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib116","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-026-04238-1","article-title":"Circulating tumor DNA-guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities","volume":"24","author":"Liu","year":"2026","journal-title":"World J. Surg. Oncol."},{"issue":"14","key":"10.1016\/j.mam.2026.101476_bib117","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-Promoting desmoplasia is disrupted by depleting FAP-Expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.mam.2026.101476_bib118","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.mam.2026.101476_bib119","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJM199305203282001","article-title":"Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group","volume":"328","author":"Lowenfels","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib120","first-page":"1632","article-title":"Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer","volume":"115","author":"Lu","year":"2002","journal-title":"Chin Med J (Engl)"},{"issue":"7913","key":"10.1016\/j.mam.2026.101476_bib121","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"Luksza","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib122","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/j.gastro.2017.11.009","article-title":"Prevalence of Microsatellite instability in intraductal papillary mucinous neoplasms of the pancreas","volume":"154","author":"Lupinacci","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib123","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","article-title":"Metabolic interactions in the tumor microenvironment","volume":"27","author":"Lyssiotis","year":"2017","journal-title":"Trends Cell Biol."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib124","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamasurg.2023.7872","article-title":"Implementation of best practices in pancreatic cancer care in the Netherlands: a stepped-wedge randomized clinical trial","volume":"159","author":"Mackay","year":"2024","journal-title":"JAMA Surg."},{"issue":"46","key":"10.1016\/j.mam.2026.101476_bib125","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.3748\/wjg.v12.i46.7433","article-title":"The genetics of nicotine dependence: relationship to pancreatic cancer","volume":"12","author":"MacLeod","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib126","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib127","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1053\/j.gastro.2022.07.047","article-title":"Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis","volume":"163","author":"Mahajan","year":"2022","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib128","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","article-title":"Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma","volume":"42","author":"Mahaseth","year":"2013","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib129","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41431-023-01301-3","article-title":"Abdominal obesity is a more important causal risk factor for pancreatic cancer than overall obesity","volume":"31","author":"Maina","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib130","article-title":"Advances in pancreatic cancer early diagnosis, prevention, and treatment: the past, the present, and the future","volume":"76","author":"Mannucci","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib131","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib132","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccell.2019.11.004","article-title":"The Tumor microbiome in pancreatic cancer: Bacteria and beyond","volume":"36","author":"McAllister","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mam.2026.101476_bib133","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241253113","article-title":"Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series","volume":"16","author":"Mehdi","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib135","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/0008-5472.CAN-12-1453","article-title":"Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals","volume":"73","author":"Miyabayashi","year":"2013","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.mam.2026.101476_bib136","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib137","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1940-6207.CAPR-10-0038","article-title":"The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D\/+ transgenic mouse model","volume":"3","author":"Mohammed","year":"2010","journal-title":"Cancer Prev. Res."},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib138","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.4049\/jimmunol.172.12.7341","article-title":"Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell","volume":"172","author":"Monti","year":"2004","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.mam.2026.101476_bib139","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib141","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41556-024-01372-4","article-title":"Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis","volume":"26","author":"Murthy","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"14","key":"10.1016\/j.mam.2026.101476_bib142","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315509121","article-title":"The MUC1-HIF-1alpha signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling","volume":"121","author":"Murthy","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib143","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib144","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020397","article-title":"Evaluating pancreatic and biliary neoplasms with small biopsy-based Next Generation Sequencing (NGS): doing more with less","volume":"14","author":"Nikas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib146","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib147","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1089\/heq.2019.0057","article-title":"Disparities in pancreatic cancer treatment and outcomes","volume":"3","author":"Noel","year":"2019","journal-title":"Health Equity"},{"issue":"Suppl. l_8","key":"10.1016\/j.mam.2026.101476_bib148","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdz385","article-title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","volume":"30","author":"O'Reilly","year":"2019","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.mam.2026.101476_bib149","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and Cisplatin with or without Veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/oem.57.5.316","article-title":"Occupational exposures and pancreatic cancer: a meta-analysis","volume":"57","author":"Ojajarvi","year":"2000","journal-title":"Occup. Environ. Med."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib151","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccell.2015.11.002","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"28","author":"Ozdemir","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib152","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.gastro.2022.09.028","article-title":"Prospective, Multi-Institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts","volume":"164","author":"Paniccia","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib153","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib154","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial efficacy of Olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination-proficient pancreatic cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib155","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10555-021-09979-x","article-title":"The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance","volume":"40","author":"Patil","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13070872","article-title":"Evaluating metabolite-based biomarkers for early diagnosis of pancreatic cancer: a systematic review","volume":"13","author":"Perazzoli","year":"2023","journal-title":"Metabolites"},{"issue":"20","key":"10.1016\/j.mam.2026.101476_bib157","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","article-title":"ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage","volume":"77","author":"Perkhofer","year":"2017","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.mam.2026.101476_bib158","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","article-title":"ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage","volume":"77","author":"Perkhofer","year":"2017","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib159","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.canlet.2013.08.015","article-title":"Chronic pancreatitis: a path to pancreatic cancer","volume":"345","author":"Pinho","year":"2014","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib160","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib161","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib162","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.mam.2026.101476_bib163","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib164","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12885-021-08388-1","article-title":"Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition","volume":"21","author":"Ramaker","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11523-020-00714-0","article-title":"Phase Ib trial of the PI3K inhibitor Copanlisib combined with the allosteric MEK inhibitor refametinib in patients with advanced cancer","volume":"15","author":"Ramanathan","year":"2020","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044238","article-title":"Advances in liquid biopsy technology and implications for pancreatic cancer","volume":"24","author":"Raufi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib167","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"issue":"22","key":"10.1016\/j.mam.2026.101476_bib168","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of maintenance Rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.mam.2026.101476_bib169","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"issue":"7963","key":"10.1016\/j.mam.2026.101476_bib171","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib172","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/gutjnl-2023-330941","article-title":"Oral bacteria accelerate pancreatic cancer development in mice","volume":"73","author":"Saba","year":"2024","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib173","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib174","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030870","article-title":"Pancreatic cancer incidence trends by race, ethnicity, Age and sex in the United States: a population-based Study, 2000-2018","volume":"15","author":"Samaan","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib175","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cmet.2015.08.015","article-title":"MYC\/PGC-1alpha balance determines the Metabolic phenotype and plasticity of pancreatic cancer stem cells","volume":"22","author":"Sancho","year":"2015","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib176","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00000658-200208000-00001","article-title":"Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis","volume":"236","author":"Schafer","year":"2002","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib177","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2009.03.017","article-title":"Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells","volume":"137","author":"Scholl","year":"2009","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.mam.2026.101476_bib178","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1158\/1078-0432.CCR-06-0292","article-title":"PIK3CA mutations in intraductal papillary mucinous neoplasm\/carcinoma of the pancreas","volume":"12","author":"Schonleben","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib179","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0092-8674(00)81079-X","article-title":"Role of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.mam.2026.101476_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713340","article-title":"Circulating microRNAs as potential biomarkers in pancreatic cancer-advances and challenges","volume":"24","author":"Seyhan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib181","doi-asserted-by":"crossref","first-page":"398","DOI":"10.21873\/cgp.20391","article-title":"Targeted therapy for BRAF V600E positive pancreatic adenocarcinoma: two case reports","volume":"20","author":"Shah","year":"2023","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-022-00346-5","article-title":"Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis","volume":"8","author":"Shaya","year":"2023","journal-title":"npj Genom. Med."},{"key":"10.1016\/j.mam.2026.101476_bib183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib184","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib185","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib186","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic cancer: opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib187","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1245\/s10434-025-18848-8","article-title":"PancreaSeq genomic classifier (PancreaSeq GC) improves pancreatic cyst classification and detection of advanced neoplasia: a multi-institutional validation Study","volume":"33","author":"Singhi","year":"2026","journal-title":"Ann. Surg Oncol."},{"issue":"29","key":"10.1016\/j.mam.2026.101476_bib188","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.mam.2026.101476_bib189","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1093\/nar\/16.16.7773","article-title":"KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas","volume":"16","author":"Smit","year":"1988","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib190","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.pan.2024.10.012","article-title":"Early detection of pancreatic cancer: study design and analytical considerations in biomarker discovery and early phase validation studies","volume":"24","author":"Smith","year":"2024","journal-title":"Pancreatology"},{"issue":"7617","key":"10.1016\/j.mam.2026.101476_bib191","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature19084","article-title":"Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion","volume":"536","author":"Sousa","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib192","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14090906","article-title":"Comprehensive genomic studies on the cell blocks of pancreatic cancer","volume":"14","author":"Souza da Silva","year":"2024","journal-title":"Diagnostics"},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib193","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/aje\/153.7.680","article-title":"Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers","volume":"153","author":"Stolzenberg-Solomon","year":"2001","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib194","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-22-0412","article-title":"Spectrum of response to platinum and PARP inhibitors in germline BRCA-Associated pancreatic cancer in the clinical and preclinical setting","volume":"13","author":"Stossel","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040794","article-title":"Clinical evaluation of the pancreatic cancer microenvironment: opportunities and challenges","volume":"16","author":"Szczepanski","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.mam.2026.101476_bib197","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/cas.15249","article-title":"Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer","volume":"113","author":"Takano","year":"2022","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib198","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2073785","article-title":"Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils","volume":"14","author":"Tan","year":"2022","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib199","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013502","article-title":"Pancreatic cancer intrinsic PI3Kalpha activity accelerates metastasis and rewires macrophage component","volume":"13","author":"Thibault","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib200","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib201","first-page":"26","article-title":"Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis","volume":"12","author":"Trikudanathan","year":"2011","journal-title":"JOP"},{"issue":"2","key":"10.1016\/j.mam.2026.101476_bib202","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0002-9440(10)63329-9","article-title":"Functional defects in the Fanconi anemia pathway in pancreatic cancer cells","volume":"165","author":"van der Heijden","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib203","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol."},{"issue":"7524","key":"10.1016\/j.mam.2026.101476_bib204","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"issue":"7664","key":"10.1016\/j.mam.2026.101476_bib205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.mam.2026.101476_bib206","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"7540","key":"10.1016\/j.mam.2026.101476_bib207","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mam.2026.101476_bib208","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/bjs.4484","article-title":"Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma","volume":"91","author":"Wagner","year":"2004","journal-title":"Br. J. Surg."},{"issue":"10409","key":"10.1016\/j.mam.2026.101476_bib209","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12943-023-01870-3","article-title":"Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.mam.2026.101476_bib211","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mam.2026.101476_bib212","article-title":"Vemurafenib combined with trametinib significantly benefits the survival of a patient with stage IV pancreatic ductal adenocarcinoma with BRAF V600E mutation: a case report","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"10018","key":"10.1016\/j.mam.2026.101476_bib213","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib214","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090316","article-title":"The extracellular matrix and pancreatic cancer: a complex relationship","volume":"10","author":"Weniger","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mam.2026.101476_bib215","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1017\/S1462399411001876","article-title":"Oncolytic virotherapy for pancreatic cancer","volume":"13","author":"Wennier","year":"2011","journal-title":"Expert Rev Mol Med"},{"issue":"8","key":"10.1016\/j.mam.2026.101476_bib216","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","article-title":"Emerging mechanisms and promising approaches in pancreatic cancer metabolism","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib217","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12916-022-02647-z","article-title":"Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA","volume":"20","author":"Wu","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib218","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13277-014-2883-z","article-title":"SMAD4 and its role in pancreatic cancer","volume":"36","author":"Xia","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib219","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.mam.2026.101476_bib220","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/1078-0432.CCR-19-4060","article-title":"Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting","volume":"26","author":"Yaeger","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.mam.2026.101476_bib221","doi-asserted-by":"crossref","first-page":"G1397","DOI":"10.1152\/ajpgi.2001.281.6.G1397","article-title":"Role of T cells in development of chronic pancreatitis in male Wistar Bonn\/Kobori rats: effects of tacrolimus","volume":"281","author":"Yamada","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"7806","key":"10.1016\/j.mam.2026.101476_bib222","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mam.2026.101476_bib223","article-title":"Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation","volume":"5","author":"Yang","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"13","key":"10.1016\/j.mam.2026.101476_bib224","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-19-3313","article-title":"A multianalyte Panel consisting of extracellular vesicle miRNAs and mRNAs, cfDNA, and CA19-9 shows utility for diagnosis and staging of pancreatic ductal adenocarcinoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.mam.2026.101476_bib225","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.24.00287","article-title":"Development and validation of a cell-free DNA fragmentomics-based model for early detection of pancreatic cancer","volume":"43","author":"Yin","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.mam.2026.101476_bib226","first-page":"36","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"39","author":"Ying","year":"2025","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib227","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-025-01696-0","article-title":"KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma","volume":"18","author":"Yousef","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.mam.2026.101476_bib228","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.2948","article-title":"Diabetes, weight change, and pancreatic cancer risk","volume":"6","author":"Yuan","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mam.2026.101476_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib230","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1038\/s41467-023-40727-7","article-title":"Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mam.2026.101476_bib231","article-title":"Association between hepatitis B or hepatitis C virus infection and risk of pancreatic cancer: a systematic review and meta-analysis of cohort studies","volume":"10","author":"Zhao","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib232","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-017-0624-9","article-title":"The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer","volume":"16","author":"Zhou","year":"2017","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2026.101476_bib233","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12967-021-02882-7","article-title":"The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing","volume":"19","author":"Zhou","year":"2021","journal-title":"J. Transl. Med."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299726000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299726000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:31:02Z","timestamp":1781915462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299726000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":233,"alternative-id":["S0098299726000324"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2026.101476","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2026.101476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101476"}}